607 related articles for article (PubMed ID: 32146413)
21. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
Burslem GM; Crews CM
Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
[TBL] [Abstract][Full Text] [Related]
22. Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety.
Zhang R; Xie S; Ran J; Li T
J Cell Physiol; 2024 May; 239(5):e31255. PubMed ID: 38501341
[TBL] [Abstract][Full Text] [Related]
23. Applications of protein ubiquitylation and deubiquitylation in drug discovery.
Chen Y; Xue H; Jin J
J Biol Chem; 2024 May; 300(5):107264. PubMed ID: 38582446
[TBL] [Abstract][Full Text] [Related]
24. Protein degradation: a validated therapeutic strategy with exciting prospects.
Lebraud H; Heightman TD
Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
[TBL] [Abstract][Full Text] [Related]
25. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
Wang C; Zhang Y; Xing D; Zhang R
Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
[TBL] [Abstract][Full Text] [Related]
26. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
Yang W; Saboo S; Zhou L; Askin S; Bak A
Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
[TBL] [Abstract][Full Text] [Related]
27. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
28. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
29. Target Validation Using PROTACs: Applying the Four Pillars Framework.
Nowak RP; Jones LH
SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
[TBL] [Abstract][Full Text] [Related]
30. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-MartÃnez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
31. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
Wu Y; Zhang J; Zhu X; Zhang Y
Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
[TBL] [Abstract][Full Text] [Related]
32. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
33. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Barghout SH
Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
Yokoo H; Naganuma M; Oba M; Demizu Y
Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
[TBL] [Abstract][Full Text] [Related]
35. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
[TBL] [Abstract][Full Text] [Related]
36. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
37. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications.
Heitel P
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677746
[TBL] [Abstract][Full Text] [Related]
38. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
40. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon S; Lee BH
Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]